Abstract 10195: Comparing the Antiplatelet and Antithrombotic Effects of CCG263719 and SLUG001, Second Generation 12-Lipoxygenase Inhibitors, to ML355
Abstract
Background: Platelet-mediated thrombosis is a major contributor to myocardial infarction and other cardiovascular diseases. Reperfusion following ischemia can further exacerbate tissue injury, in part through platelet activation and inflammatory signaling. Platelet 12(S)-lipoxygenase (12-LOX), an oxygenase that promotes platelet activation through the generation of bioactive oxylipins including 12-hydroxyeicosatetraenoic acid (12-HETE), has also been implicated in ischemia-reperfusion injury. Our laboratory previously developed ML355, a selective 12-LOX inhibitor that demonstrates antiplatelet and antithrombotic efficacy without increasing bleeding risk. Two second-generation inhibitors, SLUG001 and CCG263719, were subsequently identified. SLUG001 exhibited 7.2-fold greater potency and improved selectivity in enzymatic assays, while CCG263719 demonstrated improved antiplatelet activity. Here, we compared the efficacy of SLUG001 and CCG263719 to ML355 in human platelets and in vivo models of thrombosis and myocardial reperfusion injury. Methods: Isolated human platelets and human whole blood were incubated with 12-LOX inhibitors prior to assessment of platelet activation by aggregation, integrin activation, and granule secretion. Further, Ex vivo thrombus formation was evaluated using the Total Thrombus Formation Analysis System. In vivo efficacy was assessed using laser-induced cremaster arteriole thrombosis and myocardial ischemia-reperfusion injury models. Results: Both second-generation compounds inhibited collagen- and thrombin-induced platelet aggregation in a dose-dependent manner. CCG263719 demonstrated greater potency than ML355 and SLUG001 in collagen-stimulated aggregation, integrin activation, and granule secretion, whereas SLUG001 and ML355 exhibited similar activity. Among the inhibitors tested, only CCG263719 significantly reduced ex vivo thrombus formation. Both CCG263719 and SLUG001 inhibited thrombus formation in vivo following intravenous administration, although SLUG001 exhibited a delayed onset of activity. SLUG001 and CCG263719 demonstrated antithrombotic efficacy following oral administration and were bioavailable. In a myocardial ischemic-reperfusion injury model, both second-generation inhibitors reduced infarct size following transient occlusion of the left anterior descending coronary artery. Conclusions: Although SLUG001 exhibited superior potency in enzymatic assays, CCG263719 produced the most robust antiplatelet effects. Together, these data support continued development of next-generation 12-LOX inhibitors as a novel therapeutic strategy for thrombotic cardiovascular diseases, including myocardial infarction and ischemia-reperfusion injury, while potentially avoiding the bleeding liabilities associated with current antiplatelet therapies.